BBlogFlow

Interior Health restores services in Clinton - CFJC Today Kamloops

·Aug 16, 2026
Source: CFJC Today Kamloops
Read the original article

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email

This article is an excerpt. To read the full content, visit the original source. CFJC Today Kamloops

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

Optogenetic Therapy Restores Partial Vision - Optics & Photonics News

A gene therapy makes surviving retinal ganglion cells light-sensitive, allowing blind patients to detect objects using stimulating goggles. [Image: IOB, Veronique Juvin, 2021] An international team of researchers has shown that optogenetic therapy can improve the vision of people who have become blind through an inherited eye disease (N. Engl. J. Med., doi: 10.1056/NEJMoa2602215). Clinical tests showed that seven out of the 10 patients became more sensitive to light while some of the participants were also able to detect and reach for specific objects.

Optics & Photonics News·

Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Medical Xpress·

Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.

Oncodaily·